The Cambridge Biomedical Campus sits in CB2, two miles south of the city centre, sharing postcodes with Addenbrooke's Hospital and the Wellcome Sanger Institute's Hinxton corridor. AstraZeneca relocated its global headquarters here in 2016. GSK runs discovery research operations across buildings that share access roads with University of Cambridge clinical departments. Vertex and Alnylam occupy the perimeter. The salary market operating inside those buildings for AI and ML engineers is not the King's Cross AI corridor market. The Cambridge Biomedical Campus is a third Cambridge, where a Senior ML Scientist with a genomics or computational chemistry background earns £90K-£130K (~$114K-$165K) base and the equity instrument is an AZN NASDAQ RSU rather than a startup EMI option.
Cambridge life sciences AI roles paid £85K-£145K (~$108K-$184K) base in Q2 2026, per ENTRA's Job Signal Index (Cambridge CB2 postcode filter, 340 active AI-adjacent postings). AstraZeneca posted salary ranges on 78% of approximately 120 live UK AI roles audited by ENTRA in Q2 2026, more than double the UK AI market median of 34%. That gap is not a minor calibration difference. The spread is the largest ENTRA has recorded between a life sciences anchor employer and the UK AI market median in 2026 Salary Transparency Month coverage, and it shapes how the broader Cambridge biotech-AI hiring cluster is navigating disclosure pressure ahead of the Employment Rights Act 2025 obligations taking effect in April 2027.
The Two Cambridges: Science Park and Biomedical Campus
Cambridge's AI employer base divides into two geographically and economically distinct clusters operating within four miles of each other.
The Cambridge Science Park, in CB4 north of the city, is the technology cluster. ARM's primary research campus sits on its eastern edge, anchoring the hardware AI and semiconductor design functions that, post-NASDAQ IPO, became one of the UK's highest-profile AI engineering employers. Microsoft Research Cambridge, founded in 1997, runs approximately 80 researchers across ML systems, health AI, and cryptography in CB3. Amazon's Alexa Cambridge office and Jaguar Land Rover's AI research function hold Science Park addresses. The compensation register here is technology-native: NASDAQ-listed equity, base salaries benchmarked against Google DeepMind and NVIDIA's Cambridge Silicon AI Centre in Cambourne, and total compensation data visible on Levels.fyi.
The Cambridge Biomedical Campus operates on a different register. Base salaries for AI and ML roles cluster £85K-£145K, with equity in dual-listed pharmaceutical stocks (AZN on NASDAQ and the London Stock Exchange; GSK on the NYSE) rather than pre-IPO options. Benefits at this scale of employer include BUPA private healthcare and defined-contribution pensions above auto-enrolment minimums. Critically, the skill premium the Biomedical Campus pays for is specific: ML engineers who understand protein folding, single-cell genomics, clinical trial data architecture, or computational chemistry for drug target identification. That intersection is scarcer than general ML engineering and commands a premium that neither ARM nor DeepMind is competing for at the same depth.
The University of Cambridge AI Centre, running approximately 120 researchers across the Computer Laboratory and Clinical School, feeds both clusters. Doctoral completers with theses in medical imaging ML, clinical NLP, or genomics AI enter a market where AstraZeneca, GSK, and Microsoft Research Cambridge are simultaneously active. The offer profiles from each cluster have diverged in the 18 months since ARM's NASDAQ listing changed the reference benchmark for Cambridge comp expectations across the board.
AstraZeneca's 78%: What Biomedical Campus Disclosure Looks Like
ENTRA's Pay Transparency Audit Q2 2026 audited approximately 120 live AstraZeneca UK postings and found 78% carried a salary range visible before application. The UK AI market median is 34% by the same methodology. GSK's Cambridge discovery research function carried an estimated 58% disclosure rate on AI-adjacent UK postings in the same audit, above the market median and below AstraZeneca's rate.
A disclosed AstraZeneca Senior ML Scientist posting in the Discovery Sciences division reads as follows in Q2 2026: £90K-£130K base (per Glassdoor Cambridge data July 2026, corroborated by ENTRA's candidate-side offer corpus), AZN RSUs on a three-year NASDAQ vesting schedule with annual grant refreshes, BUPA private healthcare, and a discretionary performance bonus structure. Total compensation at the top of the Senior ML Scientist band, inclusive of RSU grant value at AZN's 2026 trading levels, sits in the £155K-£175K (~$197K-$222K) range per ENTRA's Q2 2026 Salary Survey. For an ex-Cambridge ML PhD arriving via the Global Talent visa route endorsed by the Alan Turing Institute's biomedical AI panel, that package competes credibly against a DeepMind Research Scientist entry band while offering a drug discovery research environment no King's Cross lab can replicate.
AstraZeneca's disclosure posture is partly structural. The company's dual listing on NASDAQ and the London Stock Exchange, alongside its Swiss SMI listing for European institutional access, creates pay governance infrastructure with international investor relations audiences. Publishing salary ranges on three quarters of AI job listings is a lower operational step inside a corporate pay transparency framework already running at that scale. The 78% rate is also a candidate acquisition tool: the Skilled Worker visa £38,700 general salary threshold is cleared by every AI role AstraZeneca posts, and disclosed bands that start at £90K signal to Global Talent route candidates evaluating the UK market that the Biomedical Campus competes at London-comparable rates without requiring a first screening call to confirm it.
The ARM Effect on Cambridge Comp Expectations
ARM's September 2023 NASDAQ listing produced something specific for the Cambridge compensation market that is still working through biotech-AI employer offer structures three years on.
Before the IPO, ARM's Hills Road campus, a 25-minute walk from AstraZeneca's Biomedical Campus reception, operated on a pay register competitive within Cambridge but not exceptional against London AI lab benchmarks. Post-IPO, ARM's RSU grants converted from paper value to liquid NASDAQ equity. Principal Engineers in the NPU architecture and software-hardware co-design functions reached £140K-£185K (~$178K-$235K) total compensation, per Levels.fyi Cambridge data and ENTRA's Q2 2026 offer corpus across seven Cambridge engineering agencies. That figure, visible publicly on the platform senior ML engineers benchmark against, became a reference point for every employer competing for the same talent in CB2 and CB4.
The ARM effect landed hardest on Biomedical Campus employers at the Senior Scientist and Principal Scientist bands. A Senior Computational Scientist at AstraZeneca in 2024 comparing a lateral move to ARM's co-design function was looking at a £30K-£50K total compensation uplift and liquid NASDAQ equity, with the gap documented on Levels.fyi rather than held in recruiter conversations. Two Cambridge headhunters consulted by ENTRA in Q2 2026, speaking on background, described AstraZeneca's mid-senior AI compensation review in 2024-2025 as a direct response to ARM's post-IPO visibility, a cycle that partially explains both the expanded salary ranges in AstraZeneca's current posting data and the 78% disclosure rate that reflects a deliberate decision to put those improved bands in front of candidates before the ARM comparison is made elsewhere.
ERA 2025 and the April 2027 Reckoning for Biomedical Campus Employers
The Employment Rights Act 2025, which received Royal Assent in June 2025, mandates equity action plans from April 2027 for employers with 250 or more UK employees. Every anchor employer on the Cambridge Biomedical Campus exceeds that threshold. Equity action plans build on the existing Equality Act 2010 gender pay gap reporting requirement but demand more: documented plans with measurable actions and timelines to address gaps, not merely annual disclosure of the gap figure.
AstraZeneca's FY2025 UK Gender Pay Gap Report, filed with the UK Government Gender Pay Gap Service, records a mean gender pay gap of 14.2%. That sits below the pharmaceutical industry median of approximately 18% and below the UK technology sector median of approximately 15.7%, a creditable position that nonetheless reflects underrepresentation of women in the highest-paid AI and computational biology functions, where the drug discovery ML premium drives the £130K-£145K top of the Cambridge Biomedical Campus AI range.
For AstraZeneca and its Biomedical Campus peers, ERA 2025 equity action plans create a new complexity: AI compensation at this cluster includes NASDAQ RSU grants whose value fluctuates with share price. A posted base band of £90K-£130K captures the guaranteed cash component; it does not capture the total compensation picture. The ACAS and EHRC guidance circulating on what equity action plans must document for equity-weighted total compensation is not yet settled. April 2027 is twenty months from today.
The University of Cambridge AI Centre's approximately 120 researchers, feeding both the Science Park and Biomedical Campus clusters at the doctoral and post-doctoral level, sit at the upstream point of this pipeline. Representation gaps in the Centre's senior researcher cohort translate directly into the candidate pool from which Cambridge's biotech-AI employers draw; employers documenting April 2027 equity action plans without engaging their sourcing infrastructure face a structural gap in the plan before the first action item is written.
AstraZeneca's 78% posting rate establishes what Biomedical Campus transparency leadership looks like in August 2026. The employers who have already built the infrastructure to post bands on three quarters of their AI listings are better positioned to meet the ERA 2025 documentation timeline than those still holding compensation to the verbal offer stage. Twenty months compresses faster than most Cambridge Biomedical Campus HR functions have historically moved on pay architecture decisions.
Cambridge Biomedical Campus AI salary range (£85K-£145K base) per ENTRA Job Signal Index Q2 2026, Cambridge CB2 postcode filter, 340 active AI-adjacent postings audited April-June 2026. AstraZeneca disclosure rate (78%) per ENTRA Pay Transparency Audit Q2 2026, approximately 120 live UK postings audited; AstraZeneca did not confirm this figure. GSK disclosure rate (58%) is an ENTRA estimate from the same audit methodology; GSK did not confirm. AstraZeneca Senior ML Scientist base range (£90K-£130K) per Glassdoor Cambridge data July 2026, corroborated by ENTRA Q2 2026 candidate-side offer corpus; not confirmed by AstraZeneca. ARM Principal Engineer total compensation (£140K-£185K) per Levels.fyi Cambridge data and ENTRA Q2 2026 offer corpus across seven Cambridge engineering agencies. AstraZeneca gender pay gap (14.2%) per AstraZeneca FY2025 UK Gender Pay Gap Report filed with the UK Government Gender Pay Gap Service. University of Cambridge AI Centre researcher count (~120) per Centre public communications. UK AI market median salary disclosure rate (34%) per ENTRA Pay Transparency Audit Q2 2026. Employment Rights Act 2025 received Royal Assent June 2025; equity action plan obligations effective April 2027, 250-employee threshold unchanged. Skilled Worker visa general salary threshold £38,700 per Home Office immigration salary list, effective April 2024. Global Talent visa: no minimum salary threshold; biomedical AI endorsement via Alan Turing Institute. GBP/USD conversions at £1 = $1.27 (ENTRA August 2026 canonical rate). For the Cambridge AI spinout economy drawing talent from both clusters, see Cambridge's 68 AI Spinouts. For ARM's Cambridge AI hardware hiring in full, see How Cambridge Became Britain's AI Hardware Talent Hub in H1 2026. For the broader UK AI pay transparency scorecard including ElevenLabs, Wayve, and DeepMind, see UK AI Unicorns Under the Microscope.
Global Career PlatformFind AI talent. Find your next role.
Booking is hotels. · Airbnb is apartments. · ENTRA is global careers.